Role of cytokines in the pathogenesis of inflammatory bowel disease

被引：585

作者：

Papadakis, KA ^{[1
]}

Targan, SR

机构：

[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA

[2] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Cedars Sinai Inflammatory Bowel Dis Ctr, Los Angeles, CA 90048 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2000年 / 51卷

关键词：

treatment; Crohn's disease; ulcerative colitis; tumor necrosis factor-alpha; interleukin-10;

D O I：

10.1146/annurev.med.51.1.289

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Recent advances in the drug treatment of inflammatory bowel disease (IBD) have paralleled our understanding of the pathophysiology of ulcerative colitis and Crohn's disease. Several proinflammatory and immune-regulatory cytokines are upregulated in the mucosa of patients with LED, and differences and similarities in the cytokine profiles of ulcerative colitis and Crohn's disease have been elucidated. Several clinical trials involving a chimeric anti-TNF-alpha (tumor necrosis factor-alpha) antibody have shown marked clinical benefit in the majority of patients with Crohn's disease, verifying the importance of TNF-alpha in the pathogenesis of Crohn's disease. In preliminary studies, treatment with recombinant human interleukin-10 has been beneficial in Crohn's disease but not in ulcerative colitis. Future treatment of IBD may include combination or sequential cytokine and anticytokine administration in defined groups of patients based on their mucosal cytokine profiles.

引用

页码：289 / 298

页数：10

共 27 条

[1] Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis [J].

Baert, FJ ;

D'Haens, GR ;

Peeters, M ;

Hiele, MI ;

Schaible, TF ;

Shealy, D ;

Geboes, K ;

Rutgeerts, PJ .

GASTROENTEROLOGY, 1999, 116 (01) :22-28

[2] Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses [J].

Berg, DJ ;

Davidson, N ;

Kuhn, R ;

Muller, W ;

Menon, S ;

Holland, G ;

ThompsonSnipes, L ;

Leach, MW ;

Rennick, D .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :1010-1020

[3] In vivo changes of lymphocyte subpopulations and leukocyte surface markers by multiple doses of recombinant human interleukin-10 in inflammatory bowel disease. [J].

Dejaco, C ;

Lichtenberger, C ;

Reinisch, W ;

Kuhn, I ;

Tilg, H ;

Gasche, C .

GASTROENTEROLOGY, 1998, 114 (04) :A961-A961

[4] EXPERIMENTAL-MODELS OF INFLAMMATORY BOWEL-DISEASE [J].

ELSON, CO ;

SARTOR, RB ;

TENNYSON, GS ;

RIDDELL, RH .

GASTROENTEROLOGY, 1995, 109 (04) :1344-1367

[5] The basis of current and future therapy for inflammatory bowel disease [J].

Elson, CO .

AMERICAN JOURNAL OF MEDICINE, 1996, 100 (06) :656-662

[6]

FEDORAK RN, 1998, GASTROENTEROLOGY, V114, pG3993

[7] Inflammatory bowel disease: Etiology and pathogenesis [J].

Fiocchi, C .

GASTROENTEROLOGY, 1998, 115 (01) :182-205

[8]

Fuss IJ, 1996, J IMMUNOL, V157, P1261

[9] Altered immune responses in interleukin 10 transgenic mice [J].

Hagenbaugh, A ;

Sharma, S ;

Dubinett, SM ;

Wei, SHY ;

Aranda, R ;

Cheroutre, H ;

Fowell, DJ ;

Binder, S ;

Tsao, B ;

Locksley, RM ;

Moore, KW ;

Kronenberg, M .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (12) :2101-2110

[10]

Kam LY, 1999, GASTROENTEROLOGY, V116, pA744

← 1 2 3 →